Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Sarcoma 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Human Papillomavirus-Related Cervical Carcinoma 1Advanced Fallopian Tube Carcinoma 1

Interventions

Paclitaxel 143pembrolizumab 121Carboplatin 109Bevacizumab 93Cisplatin 69Specimen Handling 62olaparib 51Magnetic Resonance Spectroscopy 51Gemcitabine 41Nivolumab 36Biopsy 36liposomal doxorubicin 34Taxes 33Cyclophosphamide 31Blood Specimen Collection 31niraparib 28lenvatinib 26Letrozole 26Doxorubicin 26Topotecan 25Drug Therapy 25Immunoglobulin G 23Brachytherapy 22fludarabine 21atezolizumab 21Radiotherapy 21Disulfides 21durvalumab 20dostarlimab 19Surveys and Questionnaires 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
adacel × Gynecologic × 1 year × Clear all
NCT05237947 2026-05-28

PRISMA

National Cancer Institute (NCI)

Phase 4 Active not recruiting
5,000 enrolled
Gynecologic

Human Papillomavirus-Related Cervical Carcinoma

NCT06639074 2025-10-02

Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial

Mayo Clinic

Phase 2 Recruiting
78 enrolled
GynecologicSarcoma

Advanced Fallopian Tube Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡